1 / 30

NEOPLASIA VI Tumor Host Interactions

NEOPLASIA VI Tumor Host Interactions. Husni Maqboul, M.D. Tumor Host Interactions. Local Effects Cancer Cachexia Paraneoplastic Syndromes Endocrinopathies Neuromyopathies Osteochondral Disorders Vascular Phenomena Fever Nephrotic Syndrome. Local Effects.

river
Download Presentation

NEOPLASIA VI Tumor Host Interactions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. NEOPLASIA VITumor Host Interactions Husni Maqboul, M.D

  2. Tumor Host Interactions • Local Effects • Cancer Cachexia • Paraneoplastic Syndromes • Endocrinopathies • Neuromyopathies • Osteochondral Disorders • Vascular Phenomena • Fever • Nephrotic Syndrome

  3. Local Effects • Tumor Impingement on nearby structures • Pituitary adenoma on normal gland, Pancreatic carcinoma on bile duct, Esophageal carcinoma on lumen • Ulceration/bleeding • Colon, Gastric, and Renal cell carcinomas

  4. Local Effects • Infection (often due to obstruction) • Pulmonary infections due to blocked bronchi (lung carcinoma), Urinary infections due to blocked ureters (cervical carcinoma) • Rupture or Infarction • Ovarian, Hepatocellular, and Adrenal cortical carcinomas; Melano-carcinoma metastases

  5. Cancer Cachexia • Progressive weakness, loss of appetite, anemia and profound weight loss (>20 lbs.) • Often correlates with tumor size and extent of metastases • Etiology includes a generalized increase in metabolism and central effects of tumor on hypothalamus • Probably related to macrophage production of TNF-a and IL-1

  6. Paraneoplastic SyndromesEndocrinopathies • Cushing’s Syndrome • Adrenal carcinoma (cortisol) more common with benign adrenal processes. • Small cell undifferentiated lung cancer (ACTH) released through cleavage of pro-opiomelano-cortin gene product. • Inappropriate ADH syndrome (Hyponatremia) • Small cell undifferentiated lung cancer (vassopressin-like hormone. • Hypothalamic tumors (vasopressin)

  7. Paraneoplastic SyndromesEndocrinopathies • Hypercalcemia(Cancer is the most common cause of hypercalcemia by either humoral or metastatic mechanisms) • Squamous cell lung cancer (PTH-like peptide) • Renal cell carcinoma (prostaglandins) • Parathyroid carcinoma (PTH) • Multiple myeloma and T-cell lymphoma (IL-1 and perhaps TGF-a) • Breast carcinoma, usually by bone metastasis

  8. Paraneoplastic SyndromesEndocrinopathies • Hypoglycemia - caused by tumor over-production of insulin or insulin like activities • Fibrosarcoma, Cerebellar hemangioma, Hepatocarcinoma • Carcinoid syndrome - Caused by serotonin, bradykinin or ?histamine produced by the tumor • Bronchial carcinoids, Pancreatic carcinoma, Carcinoid tumors of the bowel

  9. Paraneoplastic SyndromesEndocrinopathies • Polycythemia - caused by tumor production of erythropoietins • Renal cell carcinoma, Cerebellar hemangioma, Hepatocarcinoma • WDHA syndrome(watery diarrhea, hypokalemia, and achlorhydria) - caused by tumor production of vasoactive intestinal polypeptide (VIP). • Islet cell tumors, Intestinal carcinoid tumors

  10. Paraneoplastic SyndromesNeuromyopathies • Myasthenia - A block in neuromuscular transmission possibly caused by host antibodies against the tumor cells that cross react with neuronal cells or perhaps caused by toxins. • Bronchogenic carcinoma, Breast cancer • Carcinomatous Myopathy - probably immune-mediated

  11. Paraneoplastic SyndromesOsteochondral Disorders • Hypertrophic Osteoarthropy - clubbing, periosteal new bone, and arthritis • Isolated clubbing occurs in chronic obstructive pulmonary disease and in cyanotic congenital heart disease, but the full-blown syndrome is limited to lung cancer.

  12. Paraneoplastic SyndromesVascular Phenomena • Altered Coagulability - caused by the release of tumor products • Migratory Venous Thromboses (Trousseau’s sign) Pancreatic, gastric, colon, and bronchogenic carcinomas; particularly adenocarcinoma of the lung. • Marantic endocarditis - Small thrombotic vegetations on mitral or aortic valves that occur with advanced carcinomas.

  13. Paraneoplastic SyndromesFever • Associated with bacterial infections • Common where blockage of drainage occurs • Decreased immunity may play a role • Not associated with infection • Episodic as in Pel-Ebstein fever with Hodgkin’s lymphoma; poor prognostic sign in sarcomas, indicates dissemination • Likely caused by response to necrotic tumor cells and/or immune response to necrotic tumor proteins.

  14. Paraneoplastic SyndromesNephrotic Syndrome • Excessive loss of protein in the urine • probably caused by damage to renal glomeruli by tumor antigen-antibody complexes.

  15. Host Defense Against TumorsImmune Response to Tumor Antigens • Definition - coordinated biologic process designed to recognize tumor cells and their products and to kill or damage the offending cells.

  16. Host Defense Against TumorsImmune Response to Tumor Antigens • Tumor Specific Antigens (TSA) are present only on tumor cells and not on any normal cells and can be recognized by cytotoxic T-lymphocytes. • Cancer-Testis Antigens : MAGE in melanoma, lung, liver, stomach, GAGE, BAGE, RAGE • Tissue specific antigens : MART1 on normal melanocytes and melanoma • Mutational antigens : products of mutated RAS, TP53, β-catenin • Overexpressed antigens : (not recognized normally because of low concentration ) HER-2 protein in breast carcinoma • Viral antigens : HPV, EBV • Mucins : underglycosylation of tumor mucin product reveals epitopes that were covered by carbohydrates (MUC-1)

  17. Host Defense Against TumorsImmune Response to Tumor Antigens • Tumor Associated Antigens (TAA) are not unique to tumors. • Tumor-associated carbohydrate antigens • Oncofetal antigens • Expressed in embryogenesis, but not in adult tissue ( CEA, AFP) • Differentiation-specific antigens • CD10 : on neoplastic and normal B-cells • PSA : on normal and neoplastic prostatic epithelial cells • Not helpful for tumor rejection but useful for diagnosis and therapy.

  18. Evidence for immune response to tumors-I • Immune surveillance: a constant monitoring process aimed at eliminating emerging cancers. • Evidence for immune response to tumor • 1) Infiltrate of lymphocytes and macrophages associated with better prognosis in many tumors. • 2) Peripheral blood NK activity correlates with survival. • 3) Peripheral blood lymphocytes counts fall as cancer overwhelms host; patients develop anergy to skin tests.

  19. Evidence for Immune Response to Tumors-II • 4) Non-specific vaccines can stimulate macrophages and improve prognosis. IFN-g and IL-2 can stimulate NK cells and improve outcome. • 5) High incidence of some tumors in immunosupressed individuals. • 6) Spontaneous regression in some tumors. • 7) Experimental animals cured of tumor reject rechallenge by the tumor.

  20. Mechanisms of Immunity to Tumors-I • Cytotoxic T lymphocytes (CTL) - that are sensitized to TSA and perhaps other tumor antigens kill tumor cells. • Helper T lymphocytes - release IL-2 and IFN-g which stimulate CTL, macrophages, NK cells and B lymphocytes. They also produce TNF-a. • Natural Killer (NK) cells - can attack tumor cells directly without antibody coating or by Antibody Dependent Cell Cytotoxicity (ADCC) utilizing the Fc receptor on the NK cells.

  21. Mechanisms of Immunity to Tumors-II • Killer Macrophages - activated by IFN-g elaborated by Helper T lymphocytes. Participate in ADCC and can lyse tumor cells through release of TNF-a. • B lymphocytes/Plasma cells - Produce antibody directed against tumor antigens that can kill tumor cells by complement activation. • Lymphokine Activated Killer (LAK) Cells - CTL and NK cells from the tumor activated by IL-2 and IFN-g. Tumor infiltrating lymphocytes (TIL) are CTL sensitized to the tumor that can be expanded in vitro and reintroduced to the patient.

  22. Mechanisms of Tumor Resistance to Immune Response-I • Many human tumors are weakly antigenic • Reduced expression of HLA-I • Elimination of strongly immumogenic clones • Lack of costimulation • Blocking antibodies obscure tumor associated antigens (TAA). • Shed tumor antigens tie up receptors on ADCC mediating cells. • Large tumor burden produces so much TAA that tolerance develops.

  23. Mechanisms of Tumor Resistance to Immune Response-II • Antigenic evolution occurs as tumor progresses. • Genetic inability of host to respond to certain antigens. • Immunosuppression • Some tumors produce TGF-β • Increase of suppressor T-cells • Protein calorie malnutrition resulting from the tumor reduces immune response.

More Related